Search

Displaying results 7321 - 7330 of 10000 in total
  1. Drug

    BIIB021

    go.drugbank.com/drugs/DB12359
    Investigational

    BIIB021 has been investigated for the treatment of Tumors and Lymphoma.

  2. Drug

    Biphenyl dimethyl dicarboxylate

    go.drugbank.com/drugs/DB12475
    Investigational

    Nissel has been investigated for the treatment of Chronic Liver Disease.

  3. Drug

    PF-00446687

    go.drugbank.com/drugs/DB12517
    Investigational

    PF-00446687 has been investigated for the treatment of Erectile Dysfunction.

  4. Drug

    Combretastatin

    go.drugbank.com/drugs/DB12596
    Investigational

    Combretastatin has been investigated for the treatment of Anaplastic Thyroid Cancer.

  5. Drug

    Belotecan

    go.drugbank.com/drugs/DB12459
    Investigational

    Belotecan has been investigated for the treatment of Epithelial Ovarian Cancer.

    Categories: Topoisomerase I Inhibitors
  6. Drug

    Pregnenolone

    go.drugbank.com/drugs/DB02789
    ApprovedInvestigationalWithdrawn

    A 21-carbon steroid, derived from cholesterol and found in steroid hormone-producing tissues. Pregnenolone is the precursor to gonadal steroid hormones and the adrenal corticosteroids.

  7. Drug

    Tempol

    go.drugbank.com/drugs/DB12449
    Investigational

    Tempol has been used in trials studying the treatment of Anal Cancer.

    Synonyms: 4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxylCategories: Compounds used in a research, industrial, or household setting
  8. Drug

    R112

    go.drugbank.com/drugs/DB06252
    Experimental

    R112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.

  9. Drug

    PT-2385

    go.drugbank.com/drugs/DB16055
    Investigational

    PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).

  10. Drug

    Palazestrant

    go.drugbank.com/drugs/DB18971
    Investigational

    Palazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).